Yang Chi-Chun, Chen Meng-Jou, Cheng Ming-Hsuan, Fan Nai-Wen
Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan; and.
School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Cornea. 2025 Feb 18;44(10):1291-1295. doi: 10.1097/ICO.0000000000003837.
Meibomian gland dysfunction (MGD) is a global health disorder, which can have a deleterious effect on visual function and quality of life. Intense pulsed light (IPL) therapy has been shown to ameliorate MGD. However, the optimal candidates who would benefit most from IPL remain undetermined. Therefore, we aimed in this study to identify the clinical factors associated with favorable outcomes in patients with MGD after IPL therapy.
This single-center retrospective study included patients with refractory MGD treated with a course of IPL therapy combined with meibomian gland expression, with a follow-up period of 6 months. The outcome measures were the standardized patient evaluation of eye dryness (SPEED) score, tear breakup time, lid telangiectasia, meibum quality, and expressibility. Good responders were defined as those with at least a 1-point reduction in SPEED score and a 1-grade decrease in meibum quality at 6 months. Data were analyzed using the t test, chi-square test, and binary logistic regression analysis.
A total of 90 eyes in 90 patients (good responders: 48 eyes, nonresponders: 42 eyes) were included. Univariate analysis revealed that the good responders had a higher SPEED score at baseline than the nonresponders. Multivariate logistic regression analysis showed that more severe symptoms, more inspissated meibum, better expressibility, and milder degree of lid telangiectasia were independently associated with a favorable response.
Our findings suggest that patients with worse symptoms, poorer meibum quality, milder telangiectasia, or less obstruction are more likely to have a good response to IPL therapy.
睑板腺功能障碍(MGD)是一种全球性健康问题,会对视功能和生活质量产生有害影响。强脉冲光(IPL)治疗已被证明可改善MGD。然而,最能从IPL治疗中获益的最佳人选仍未确定。因此,我们在本研究中的目的是确定IPL治疗后MGD患者预后良好相关的临床因素。
这项单中心回顾性研究纳入了接受IPL治疗联合睑板腺按摩一个疗程的难治性MGD患者,随访期为6个月。结局指标包括干眼标准化患者评估(SPEED)评分、泪膜破裂时间、睑缘毛细血管扩张、睑脂质量和排出能力。良好反应者定义为在6个月时SPEED评分至少降低1分且睑脂质量降低1级的患者。数据采用t检验、卡方检验和二元逻辑回归分析。
共纳入90例患者的90只眼(良好反应者:48只眼,无反应者:42只眼)。单因素分析显示,良好反应者基线时的SPEED评分高于无反应者。多因素逻辑回归分析表明,症状更严重、睑脂更浓稠、排出能力更好以及睑缘毛细血管扩张程度较轻与良好反应独立相关。
我们的研究结果表明,症状更严重、睑脂质量更差、毛细血管扩张较轻或阻塞较少的患者对IPL治疗更可能有良好反应。